Phase 3 N=1,053 A Safety and Efficacy Study in Patients With Gastric Cancer
Gastric Cancer
Primary: Median Survival — 8.6; 7.9 Months — p=0.1983
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,091 The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines
Hepatitis b
Primary: Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders — 394; 371; 180 participants
Phase 3 N=526 Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
Influenza
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) — 2; 2; 1; 0 Participants
Phase 3 N=463 A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint — -23.9; -21.6 units on a scale — p=0.193
Phase 3 N=244 Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
Scalp Psoriasis
Primary: Patients With "Controlled Disease" in Terms of "Clear" or "Minimal" According to Investigator's Global Assessment of Disease Severity at Week 4. — 87.5; 50.8 percentage…
Phase 3 N=1,280 Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
Atrial Fibrillation
Primary: Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding — 18.04; 16.42 Events per 100 patient-years…
Phase 3 N=621 Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
Painful Diabetic Neuropathy
Primary: Number of Participants Experiencing the Occurrence of at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of…
Phase 3 N=749 MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer
Infertility
Primary: Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set — 29; 27 Percentage of participants — p=0.499
Phase 3 N=120 Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
Infections
Primary: Number of Patients With Clinical Success at the Test-Of-Cure (TOC) Visit — 65; 25; 8; 5 participants
Phase 3 N=735 Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Vasomotor Symptoms · Hot Flashes
Primary: Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) — -54.515; -54.125; -44.389; -30.020 Hot Flushes per week — p=<0.0001
Phase 3 N=208 Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
Chronic Pain · Low Back Pain
Primary: The Primary Endpoint is Defined as the Change of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6 From Week -1 (Baseline). — -2.8 Units on a scale
Phase 3 N=886 A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)
Rheumatoid Arthritis
Primary: Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE) During the 24 Week Treatment Period — 5.8; 8.0; 8.4 Percentage of Participants
Phase 3 N=1,217 Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Macular Degeneration
Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients
Phase 3 N=38 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Mitral Regurgitation
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area — 91.66; 95.74; 90.93; NA ml/m^2 — p=0.4568
Phase 3 N=405 A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: American College of Rheumatology (ACR) 20 Response at Week 14 — 10; 74; 66; 140 Participants — p=<0.001